Sort
82,697 grants matching “vaccine development”
Alphavirus Replicon Vaccines to Encephalitis Viruses
$1,044,172Jonathan Smith · Alphavax Human Vaccines, Inc. · U01 · FY2006 · AI
Vervet Research Colony as a Biomedical Resource
$1,044,153Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2025 · OD
An Advanced Vaccine Candidate To Prevent Zika Virus Infection
$1,043,638Mark K Slifka · Oregon Health & Science University · R01 · FY2021 · AI
Multicomponent vaccines for Staphylococcus aureus
$1,043,550Fan Zhang · Boston Children'S Hospital · U19 · FY2025 · AI
Biocontainment Research Support Services Core
$1,043,534Karen Marie Dobos · Colorado State University · UC7 · FY2025 · AI
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
$1,043,361Ralph C. Budd · University Of Vermont & St Agric College · P20 · FY2008 · RR
Center for Computational Mass-Spectrometry
$1,043,349Pavel A Pevzner · University Of California, San Diego · P41 · FY2012 · GM
Monitoring SIV Reservoirs with Whole Body immunoPET
$1,043,190Francois J Villinger · University Of Louisiana At Lafayette · R01 · FY2016 · AI
Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection
$1,043,172Thomas R Hawn · University Of Washington · R61 · FY2019 · AI
Multi-Center Blinded Analysis of XMRV/MLV in Chronic Fatigue Syndrome
$1,043,040W. Ian Lipkin · Columbia University Health Sciences · U54 · FY2011 · AI
Increase the number of subjects and clinical sites for currently funded project
$1,043,040W. Ian Lipkin · Columbia University Health Sciences · U54 · FY2011 · AI
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement
$1,042,983Jennifer E. Golden · University Of Tennessee Health Sci Ctr · U19 · FY2020 · AI
Vaccine and immunotherapy strategies for cancer and viruses causing cancer
$1,042,696Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA
CMV Immunotherapeutic Vaccine
$1,042,445Vical, Inc. · R44 · FY2005 · AI
Ajuvants and Toll-like Receptors in vaccine Development
$1,041,976Univ Of Massachusetts Med Sch Worcester · P01 · FY2005 · AI
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses
$1,041,945Richard K. Plemper · Georgia State University · R01 · FY2020 · AI
Host-bacterial interactions determining the spectrum of Mtb transmission
$1,041,944Padmini Salgame · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI
Task D04:World Reference Center for Emerging Viruses and Arboviruses
$1,041,919William Coale · University Of Texas Med Br Galveston · N01 · FY2013 · AI
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strains
$1,041,898Viviana A Simon · Icahn School Of Medicine At Mount Sinai · P01 · FY2023 · AI
Project 3:Optimal use of ART in establishing functional cures
$1,041,441Michael David Alpert · Scripps Florida · U19 · FY2021 · AI
Human Papillomavirus and Polyomavirus Associated Malignancies.
$1,041,403Denise A. Galloway · Fred Hutchinson Cancer Research Center · R35 · FY2018 · CA
Regulatory immune cell therapy, promotion of tolerance and underlying mechanisms in NHP renal transplantation
$1,041,302Angus W Thomson · University Of Pittsburgh At Pittsburgh · U19 · FY2022 · AI
A Novel, Logical Approach to HIV Vaccine Development
$1,041,267David I Watkins · University Of Wisconsin-Madison · R01 · FY2007 · AI
Vaccine Discovery for Chagas Disease
$1,041,153Rick L Tarleton · University Of Georgia · P01 · FY2008 · AI
Scientific Research Support Component E/ Data Management
$1,041,074Adam Godzik · Scripps Research Institute, The · UM1 · FY2012 · AI